Akihiro Tsuboi

6.8k total citations
96 papers, 3.2k citations indexed

About

Akihiro Tsuboi is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Akihiro Tsuboi has authored 96 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Molecular Biology, 27 papers in Oncology and 26 papers in Immunology. Recurrent topics in Akihiro Tsuboi's work include Renal and related cancers (74 papers), CAR-T cell therapy research (23 papers) and Immunotherapy and Immune Responses (22 papers). Akihiro Tsuboi is often cited by papers focused on Renal and related cancers (74 papers), CAR-T cell therapy research (23 papers) and Immunotherapy and Immune Responses (22 papers). Akihiro Tsuboi collaborates with scholars based in Japan, Australia and India. Akihiro Tsuboi's co-authors include Yoshitaka Oka, Haruo Sugiyama, Yusuke Oji, Manabu Kawakami, Naoki Hosen, Sumiyuki Nishida, Hiroya Tamaki, Olga A. Elisseeva, Keiko Udaka and Hiroyasu Ogawa and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Akihiro Tsuboi

93 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Akihiro Tsuboi Japan 32 2.3k 1.0k 1.0k 658 638 96 3.2k
Yusuke Oji Japan 33 3.0k 1.3× 1.3k 1.2× 1.2k 1.2× 885 1.3× 1000 1.6× 112 4.2k
Naoki Hosen Japan 28 1.7k 0.7× 791 0.8× 871 0.9× 362 0.6× 659 1.0× 111 2.9k
Camille N. Abboud United States 27 810 0.4× 783 0.8× 558 0.6× 335 0.5× 1.6k 2.5× 109 2.7k
Mårina Lafage‐Pochitaloff France 29 1.4k 0.6× 723 0.7× 873 0.9× 1.1k 1.7× 2.2k 3.5× 76 3.7k
Sumiyuki Nishida Japan 23 1.0k 0.4× 571 0.6× 554 0.6× 270 0.4× 352 0.6× 83 1.7k
Sarah K. Tasian United States 32 961 0.4× 1.3k 1.3× 575 0.6× 1.5k 2.3× 1.6k 2.5× 138 3.3k
Anna Guarini Italy 28 770 0.3× 536 0.5× 711 0.7× 622 0.9× 1.1k 1.8× 91 2.5k
Ewa Sitnicka Sweden 26 1.3k 0.6× 572 0.6× 2.1k 2.0× 207 0.3× 2.0k 3.1× 53 3.9k
Alexander Kiani Germany 25 680 0.3× 1.1k 1.1× 623 0.6× 230 0.3× 935 1.5× 78 2.7k
Erkut Bahceci United States 23 640 0.3× 796 0.8× 916 0.9× 256 0.4× 1.9k 3.0× 66 2.9k

Countries citing papers authored by Akihiro Tsuboi

Since Specialization
Citations

This map shows the geographic impact of Akihiro Tsuboi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akihiro Tsuboi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akihiro Tsuboi more than expected).

Fields of papers citing papers by Akihiro Tsuboi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akihiro Tsuboi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akihiro Tsuboi. The network helps show where Akihiro Tsuboi may publish in the future.

Co-authorship network of co-authors of Akihiro Tsuboi

This figure shows the co-authorship network connecting the top 25 collaborators of Akihiro Tsuboi. A scholar is included among the top collaborators of Akihiro Tsuboi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akihiro Tsuboi. Akihiro Tsuboi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Hashii, Yoshiko, Hiroko Nakajima, Fumihiro Fujiki, et al.. (2023). Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia. BMC Cancer. 23(1). 167–167. 5 indexed citations
3.
Fujiki, Fumihiro, Soyoko Morimoto, Kento Inoue, et al.. (2023). Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs. Cancer Immunology Immunotherapy. 72(7). 2347–2356. 1 indexed citations
4.
Nakagawa, Natsuki, Yoshiko Hashii, Hisako Kayama, et al.. (2022). An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia. Cancer Immunology Immunotherapy. 72(1). 39–53. 14 indexed citations
5.
Fujiki, Fumihiro, Soyoko Morimoto, Ayako Isotani, et al.. (2022). T Cell-Intrinsic Vitamin A Metabolism and Its Signaling Are Targets for Memory T Cell-Based Cancer Immunotherapy. Frontiers in Immunology. 13. 935465–935465. 8 indexed citations
6.
Fujiki, Fumihiro, Akihiro Tsuboi, Soyoko Morimoto, et al.. (2020). Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides. Cancer Immunology Immunotherapy. 70(1). 253–263. 7 indexed citations
7.
Hashii, Yoshiko, Yoshitaka Oka, Naoki Kagawa, et al.. (2020). Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review. Frontiers in Oncology. 10. 1188–1188. 3 indexed citations
8.
Tsuboi, Akihiro, Naoya Hashimoto, Fumihiro Fujiki, et al.. (2018). A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunology Immunotherapy. 68(2). 331–340. 43 indexed citations
9.
Kondo, Kenta, Fumihiro Fujiki, Hiroko Nakajima, et al.. (2016). An Essential Role of the Avidity of T-Cell Receptor in Differentiation of Self-Antigen-reactive CD8+ T Cells. Journal of Immunotherapy. 39(3). 127–139. 2 indexed citations
10.
Hashimoto, Naoya, Akihiro Tsuboi, Naoki Kagawa, et al.. (2015). Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. Cancer Immunology Immunotherapy. 64(6). 707–716. 34 indexed citations
11.
Ichinohasama, Ryo, Yusuke Oji, Hisayuki Yokoyama, et al.. (2010). Sensitive immunohistochemical detection of WT1 protein in tumors with anti‐WT1 antibody against WT1 235 peptide. Cancer Science. 101(5). 1089–1092. 4 indexed citations
12.
Oka, Yoshitaka, Akihiro Tsuboi, Fumihiro Fujiki, et al.. (2009). WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide. Anti-Cancer Agents in Medicinal Chemistry. 9(7). 787–797. 17 indexed citations
13.
Kawakami, Manabu, Yoshitaka Oka, Akihiro Tsuboi, et al.. (2009). Biased usage of BV gene families of T‐cell receptors of WT1 (Wilms’ tumor gene)‐specific CD8+ T cells in patients with myeloid malignancies. Cancer Science. 101(3). 594–600. 14 indexed citations
14.
Oka, Yoshitaka, Akihiro Tsuboi, Yusuke Oji, Ichiro Kawase, & Haruo Sugiyama. (2008). WT1 peptide vaccine for the treatment of cancer. Current Opinion in Immunology. 20(2). 211–220. 90 indexed citations
15.
Jomgeow, Tanyarat, Yusuke Oji, Yoko Ikeda, et al.. (2006). Wilms’ tumor gene WT1 17AA(–)/KTS(–) isoform induces morphological changes and promotes cell migration and invasion in vitro. Cancer Science. 97(4). 259–270. 57 indexed citations
16.
Ito, Ken, Yusuke Oji, Naoya Tatsumi, et al.. (2006). Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway. Oncogene. 25(30). 4217–4229. 76 indexed citations
17.
Hosen, Naoki, Masashi Yanagihara, Tsutomu Nakazawa, et al.. (2004). Identification of a gene element essential for leukemia-specific expression of transgenes. Leukemia. 18(3). 415–419. 2 indexed citations
18.
Nakano, Takashi, et al.. (2001). Flow cytometric and Ki-67 immunohistochemical analysis of cell cycle distribution of cervical cancer during radiation therapy.. PubMed. 21(4A). 2511–8. 4 indexed citations
19.
Oka, Yoshitaka, Keiko Udaka, Akihiro Tsuboi, et al.. (2000). Cancer Immunotherapy Targeting Wilms’ Tumor Gene WT1 Product. The Journal of Immunology. 164(4). 1873–1880. 160 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yusuke Oji Breakdown of academic impact, for papers by Naoki Hosen Breakdown of academic impact, for papers by Camille N. Abboud Breakdown of academic impact, for papers by Mårina Lafage‐Pochitaloff Breakdown of academic impact, for papers by Sumiyuki Nishida Breakdown of academic impact, for papers by Sarah K. Tasian Breakdown of academic impact, for papers by Anna Guarini Breakdown of academic impact, for papers by Ewa Sitnicka Breakdown of academic impact, for papers by Alexander Kiani Breakdown of academic impact, for papers by Erkut Bahceci
Rankless by CCL
2026